After the Fed released minutes of its last meeting, the bond market signaled it fears the Fed will not be aggressive enough with its rate cutting.Market Insiderread more
The Fed minutes also note that "a couple" members wanted a 50 basis point cut, based primarily on the weak inflation readings.The Fedread more
Analysts generally doubt how effective the People Bank of China's latest interest rate announcement will be in significantly helping businesses grow.China Economyread more
Japanese manufacturing activity shrank for a fourth straight month in August as export orders fell at a sharper pace.Asia Marketsread more
These in-demand skills can command top pay packets, says Feon Ang of professional networking site LinkedIn.Get Aheadread more
The Washington governor had centered his campaign around climate change, calling it "the most urgent challenge of our time."Politicsread more
The inversion is seen by many veteran traders as an important recession omen, though the timing on the eventual downturn is less predictable.Bondsread more
Here's what Nordstrom reported for its fiscal second-quarter earnings.Retailread more
The sexy image that once boosted Victoria's Secret has been haunting L Brands more recently, as women are steering clear of the brand's hot pink, lacy and bejeweled lingerie.Retailread more
Ford is one of four automakers that reached a voluntary agreement with California on fuel efficiency rules, defying Trump and his administration's effort to strip the state of...Autosread more
See which stocks are posting big moves after the bell.Market Insiderread more
Theranos, the blood-testing start-up that recently came under fire, continued to defend its technology with a blog post on Thursday.
"From his very first interactions with Theranos, the (Wall Street Journal) reporter made abundantly clear that he considered Theranos to be a target to be taken down, and not simply the subject of an objective news story. The articles that appeared last week are the inevitable product of that approach, " the company said.
Last week, the Journal published a pair ofarticles suggesting the start-up was relying on technology from traditional labs as it struggled with its own proprietary technology. The articles also reported that some former employees doubt the reliability of Edison, the company's signature lab tool. The viability of Edison, which aims to test just a few drops of blood rather than a typical amount drawn from an arm, is key to Theranos's strategy.
CEO Elizabeth Holmes has defended her company through several media appearances, including on CNBC. She acknowledged that Theranos has used technology from other labs for tests from venous draws but stressed that the company relies on its own technology for finger-stick tests. She noted that Theranos has received FDA approval for one test and expects to get clearance for others.
In the blog post posted Thursday, the company lists what it claims are factual errors in the Journal's reporting and responded to each.
"The reporter raises questions regarding whether Theranos' proficiency-testing protocols comply with regulations. But the approach that the reporter describes is unremarkable: It's just a description of Theranos' alternative assessment procedures. Theranos has explained our process to our regulators, and proficiency testing at Theranos meets the regulatory requirements."
Theranos, which has a valuation of $9 billion, promised to shake up medical testing by conducting a wide range of tests with one drop of blood from a finger-stick, rather than the large vial typically collected.
The Journal stands by its reporting on the company.
"The Journal reiterates that our articles about Theranos were thoroughly reported, fair and wholly accurate, " the newspaper said in a statement.
— Reuters contributed to this report.